Cure My Disease

Don't miss your cure!

 Log in / Sign up

New approach fights resistant prostate cancer with testosterone flip

NCT ID NCT06922318

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 22, 2026 · Updated 23 times

Summary

This study is testing whether giving testosterone along with an experimental drug (ZEN-3694) first, followed by a standard prostate cancer drug (enzalutamide) plus ZEN-3694, can shrink tumors in men whose prostate cancer has spread and stopped responding to standard treatments. Researchers want to see if starting with testosterone makes the later treatment work better. The study will involve about 50 men with metastatic prostate cancer that has become resistant to hormone-blocking therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER